Royalty Pharma plc
In the published model solve dated 2026-Q2, anchored at $60.75, Royalty Pharma plc (RPRX) is priced for +8.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Royalty Pharma is not a drugmaker; it buys royalty streams on approved and late-stage drugs, which is why it runs a 65% operating margin on about $2.4B of revenue without owning a single lab bench. • The whole business is a treadmill: existing royalties decline as patents expire, so new investment must continually replace them, and the company deployed $528 million in Q1 2026 alone [Source: Royalty Pharma Q1 2026 earnings release, May 2026]. • The watch item is portfolio receipts: management r
Is RPRX overvalued? See what's priced in →
567 institutional managers reported holding RPRX in 13F filings for the quarter ended 2026-03-31. Together they hold about 64% of the company; the top 10 hold 35%. 95 opened new positions that quarter. Held by Morgan Stanley, BlackRock, FMR (Fidelity), among others. On the short side, 11.1M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RPRX's share count grew 6.7% over the past five years even with $1.81B spent on repurchases. It pays no dividend. Cash returned over the past three years: $1.68B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RPRX over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RPRX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | -4.7% | -7.6% |
| 2023-08-09 | -0.8% | -11.2% |
| 2023-11-09 | -0.5% | +4.4% |
| 2024-05-10 | +0.3% | -4.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RPRX's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-06-04 (items 5.07); 2026-05-28 (items 1.01, 2.03, 9.01); 2026-05-06 (items 2.02, 9.01); 2026-04-13 (items 7.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.